Alzheimer's disease

A new phase in the treatment of Alzheimers disease is expected to begin in 2009 with the launch of drugs that slow the progression of the disease - Alzhemed and Flurizan.

Furthermore, selection of individuals from Alzheimers disease subgroups or those more likely to get the disease, can lead to better efficacy demonstration and lower required recruitment numbers.

Identify potential patient segments in Alzheimers Disease for key late-stage compounds and rank future products